Wall Street brokerages expect Akari Therapeutics PLC (NASDAQ:AKTX) to announce earnings of ($1.00) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Akari Therapeutics’ earnings. Akari Therapeutics reported earnings of ($0.08) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 1,150%. The firm is expected to report its next earnings report on Friday, March 30th.
On average, analysts expect that Akari Therapeutics will report full-year earnings of ($1.78) per share for the current financial year, with EPS estimates ranging from ($2.00) to ($1.55). For the next financial year, analysts expect that the company will post earnings of ($3.00) per share. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that cover Akari Therapeutics.
Several brokerages have recently weighed in on AKTX. ValuEngine upgraded Akari Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, September 11th. Zacks Investment Research raised Akari Therapeutics from a “hold” rating to a “strong-buy” rating and set a $6.50 price objective for the company in a research note on Wednesday, September 20th. William Blair raised Akari Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Friday, September 22nd. Canaccord Genuity reissued a “buy” rating and set a $15.00 price objective on shares of Akari Therapeutics in a research note on Friday, September 22nd. Finally, Chardan Capital reaffirmed a “neutral” rating on shares of Akari Therapeutics in a research note on Sunday, September 17th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. Akari Therapeutics currently has a consensus rating of “Hold” and an average price target of $7.50.
A hedge fund recently raised its stake in Akari Therapeutics stock. VHCP Management II LLC grew its position in shares of Akari Therapeutics PLC (NASDAQ:AKTX) by 15.4% during the second quarter, according to its most recent filing with the SEC. The firm owned 426,297 shares of the biopharmaceutical company’s stock after acquiring an additional 56,807 shares during the period. Akari Therapeutics comprises about 0.8% of VHCP Management II LLC’s holdings, making the stock its 13th largest holding. VHCP Management II LLC owned about 3.62% of Akari Therapeutics worth $1,965,000 at the end of the most recent reporting period. 20.95% of the stock is currently owned by hedge funds and other institutional investors.
Akari Therapeutics (NASDAQ:AKTX) traded down $0.20 during trading hours on Tuesday, reaching $4.33. The company’s stock had a trading volume of 163,643 shares, compared to its average volume of 374,082. Akari Therapeutics has a twelve month low of $3.18 and a twelve month high of $22.20. The stock has a market capitalization of $54.65, a P/E ratio of -15.46 and a beta of -9.06.
TRADEMARK VIOLATION NOTICE: This piece of content was posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.thelincolnianonline.com/2018/01/13/1-00-earnings-per-share-expected-for-akari-therapeutics-plc-aktx-this-quarter-updated-updated.html.
About Akari Therapeutics
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.